Createrna Science

Focus: Createrna Science is an early-stage Shanghai-based biotech focused on small molecule therapeutics across respiratory, nephrology, and cardiovascular indications. Founded in 2023, the company is pre-revenue with an active pipeline in clinical development.

Respiratory Nephrology Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Createrna Science

AI assessmentNot Hiring

No open roles listed right now. Follow Createrna Science to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Clinical Trials (1)

NCT06543459To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

Phase 1

Help build intelligence for Createrna Science

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded biotech with 12 active clinical programs across high-need therapeutic areas
Pipeline breadth across PNH, IgA nephropathy, hypertension, and cough with multiple programs in Phase 2/3, suggesting near-term clinical readouts
Shanghai-based location provides exposure to Asia-Pacific drug development and regulatory pathways for growing pharma market

Watch Out For

Company is less than 2 years old with no disclosed funding, financial position, or revenue—significant execution and capitalization risk
Zero active job openings and no employee count data suggest either very early stage hiring freeze or limited public visibility into hiring plans

Generated by Claude from Createrna Science's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Clinical Trials (1)

NCT05828485Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects

Phase 1

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Clinical Trials (1)

NCT05828472A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Phase 1

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Clinical Trials (1)

NCT05642585A Study of Single-dose MY008211A in Healthy Adults

Phase 1

MY008211A tablets

IgA Nephropathy (IgAN)

Phase 2

Clinical Trials (1)

NCT06687174Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Phase 2

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Clinical Trials (1)

NCT06050226A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

QR052107B 100 mg

Cough

Phase 2

Clinical Trials (1)

NCT06920836QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study

Phase 2

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Clinical Trials (1)

NCT06134414Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2/3

Clinical Trials (1)

NCT06933914Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 2/3

MY008211A tablets

Paroxysmal Nocturnal Hemoglobinuria

Phase 3

Clinical Trials (1)

NCT06932471Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Phase 3

MY008211A tablets

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Phase 3

Clinical Trials (1)

NCT06932744Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Phase 3

QR12000 75mg

Essential Hypertension

Phase 3

Clinical Trials (1)

NCT06716970QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Phase 3